Drug profile · INN
etoposide
ETOPOPHOS
etoposide (ETOPOPHOS) is a dna topoisomerase ii inhibitor. Associated with Sandoz Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
Drug details — etoposide
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 0
- Programs
- 59
- Data quality
- 0.89
Quick answer
etoposide (ETOPOPHOS) is a dna topoisomerase ii inhibitor. Associated with Sandoz Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
DNA topoisomerase II inhibitor
Primary target: DNA topoisomerase II
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| TGA | approved | — |
| NMPA | clinical trials | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is etoposide?
etoposide (ETOPOPHOS) is a dna topoisomerase ii inhibitor. Associated with Sandoz Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for etoposide?
ETOPOPHOS is a marketed brand name for etoposide. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of etoposide?
etoposide has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.